Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Participate in Upcoming Investor Conferences

ITM to participate in three upcoming industry investor conferences hosted by Jefferies, William Blair, and Brookline Capital Markets.
October 23, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Radiopharmaceutical CDMO Market Size/Share Worth USD 7.2 Billion by 2034 at a 9.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Radiopharmaceutical CDMO Market Size, Trends and Insights By Application...
October 18, 2025 03:00 ET | Source: AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer...
October 17, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its...
October 16, 2025 06:52 ET | Source: Research and Markets

Nuclear Medicine Equipment Market Analysis Report 2025-2035

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Equipment Market - A Global and Regional Analysis: Focus on Application, End User, Country, and Region - Analysis and Forecast,...
October 16, 2025 02:00 ET | Source: AdvanCell

AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors

Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a...
October 12, 2025 18:05 ET | Source: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
September 29, 2025 07:00 ET | Source: AdvanCell

AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25

Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six...
September 04, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual...
August 19, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and...